Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

pertuzumab

Roche - Basel

Roche leads pharma R&D spend for 2013

Top 30 pharma companies spent a total of $112bn on research

- PMLiVE

NICE recommends Pradaxa in blood clot indication

Boehringer drug backed to treat and prevent deep vein thrombosis and pulmonary embolism

- PMLiVE

NICE backs Pfizer drug in kidney cancer

Inlyta near end of two-year struggle for recommendation

- PMLiVE

Roche and Exelixis file melanoma duo in US

Combination of cobimetinib and Zelboraf improved progression-free survival by 9.9 months

- PMLiVE

Novartis’ Afinitor fails frontline breast cancer trial

Drug already approved to treat HER2-negative breast cancer

- PMLiVE

Roche’s early development head Richard Scheller to retire

Will be replaced by Michael Varney from the company's Genentech business

- PMLiVE

Cancer Drugs Fund is not NICE replacement

Malcolm Qualie, pharmacy lead for specialised services within NHS England, speaks to PMLiVE

- PMLiVE

Merck to start major trial of Keytruda in breast cancer

PD-1 immunotherapy is already available as treatment for melanoma

- PMLiVE

UK Labour party pledges £330m cancer fund

Says will improve access to cancer drugs, radiotherapy and surgery if elected

- PMLiVE

Cancer care celebrated at awards

QiC Oncology programme recognises teams working to improve patient outcomes in oncology

UK flag

Education at heart of new UK diabetes guidelines

NICE recommends new standards for adults with type 1 and children with either type 1 or type 2

National Institute for Health and Care Excellence NICE logo

Janssen sways NICE with Stelara discount

UK health watchdog set to recommend drug in psoriatic arthritis after agreeing patient access scheme

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links